EUK Stock Overview
EuKedos S.p.A. provides managed and long-term care services in Italy.
Price History & Performance
|Historical stock prices|
|Current Share Price||€1.42|
|52 Week High||€3.50|
|52 Week Low||€1.16|
|1 Month Change||4.81%|
|3 Month Change||-4.39%|
|1 Year Change||12.30%|
|3 Year Change||36.06%|
|5 Year Change||34.76%|
|Change since IPO||-98.88%|
Recent News & Updates
Is EuKedos (BIT:EUK) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Here's What To Make Of EuKedos' (BIT:EUK) Decelerating Rates Of Return
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...
|EUK||IT Healthcare||IT Market|
Return vs Industry: EUK exceeded the Italian Healthcare industry which returned -27.4% over the past year.
Return vs Market: EUK exceeded the Italian Market which returned -15.3% over the past year.
|EUK Average Weekly Movement||7.4%|
|Healthcare Industry Average Movement||6.5%|
|Market Average Movement||5.1%|
|10% most volatile stocks in IT Market||7.8%|
|10% least volatile stocks in IT Market||3.2%|
Stable Share Price: EUK is more volatile than 75% of Italian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: EUK's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
EuKedos S.p.A. provides managed and long-term care services in Italy. The company offers residential social care services to elderly, self-sufficient, or incapacitated adults. It manages healthcare and assistance residences with 1,345 beds in the North and Central Italy, primarily located in Lombardy, Piedmont, Abruzzo, Valle D'Aosta, and Emilia Romagna.
EuKedos Fundamentals Summary
|EUK fundamental statistics|
Is EUK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EUK income statement (TTM)|
|Cost of Revenue||€33.25m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.025|
|Net Profit Margin||1.30%|
How did EUK perform over the long term?See historical performance and comparison
Is EUK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EUK?
Other financial metrics that can be useful for relative valuation.
|What is EUK's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does EUK's PE Ratio compare to its peers?
|EUK PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
SRI Servizi Italia
HI Health Italia
SVS Svas Biosana
Price-To-Earnings vs Peers: EUK is expensive based on its Price-To-Earnings Ratio (56.5x) compared to the peer average (19.6x).
Price to Earnings Ratio vs Industry
How does EUK's PE Ratio compare vs other companies in the European Healthcare Industry?
Price-To-Earnings vs Industry: EUK is expensive based on its Price-To-Earnings Ratio (56.5x) compared to the Italian Healthcare industry average (24.1x)
Price to Earnings Ratio vs Fair Ratio
What is EUK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||56.5x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EUK's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of EUK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EUK (€1.42) is trading above our estimate of fair value (€0.67)
Significantly Below Fair Value: EUK is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is EuKedos forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EuKedos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has EuKedos performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EUK has a large one-off gain of €1.0M impacting its December 31 2021 financial results.
Growing Profit Margin: EUK became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: EUK has become profitable over the past 5 years, growing earnings by -3.5% per year.
Accelerating Growth: EUK has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: EUK has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (26.6%).
Return on Equity
High ROE: EUK's Return on Equity (2%) is considered low.
Discover strong past performing companies
How is EuKedos's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: EUK's short term assets (€13.6M) do not cover its short term liabilities (€16.5M).
Long Term Liabilities: EUK's short term assets (€13.6M) do not cover its long term liabilities (€104.8M).
Debt to Equity History and Analysis
Debt Level: EUK's net debt to equity ratio (40.4%) is considered high.
Reducing Debt: EUK's debt to equity ratio has increased from 63.3% to 66.1% over the past 5 years.
Debt Coverage: EUK's debt is well covered by operating cash flow (29.5%).
Interest Coverage: EUK's interest payments on its debt are not well covered by EBIT (1.1x coverage).
Discover healthy companies
What is EuKedos's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EUK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EUK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EUK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EUK's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: EUK is not paying a notable dividend for the Italian market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EUK has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carlo Iuculano (60 yo)
Mr. Carlo Iuculano has been the Chairman at EuKedos S.p.A. since November 4, 2011 and has been its Chief Executive Officer since June 20, 2013 and also served as its President. Mr. Iuculano served as a Man...
CEO Compensation Analysis
Compensation vs Market: Carlo's total compensation ($USD239.74K) is below average for companies of similar size in the Italian market ($USD363.91K).
Compensation vs Earnings: Carlo's compensation has been consistent with company performance over the past year.
Experienced Management: EUK's management team is seasoned and experienced (9.2 years average tenure).
Experienced Board: EUK's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
EuKedos S.p.A.'s employee growth, exchange listings and data sources
- Name: EuKedos S.p.A.
- Ticker: EUK
- Exchange: BIT
- Founded: NaN
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: €32.179m
- Shares outstanding: 22.74m
- Website: https://www.eukedos.it
Number of Employees
- EuKedos S.p.A.
- Via Benedetto Da Foiano, 14
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.